Microbiologics Acquires Diagnostic Quality Controls Manufacturer SensID

SensID is known for precision and innovation, particularly within the oncology space. The company specializes in providing intensely characterized reference materials and quality controls used for R&D, validation, and quality control of molecular diagnostic tests. SensID’s recent innovations include launching the first ESR1 mutations reference set for validation of cell-free DNA mutation detection methods, as well as a platform-agnostic control for dihydropyrimidine dehydrogenase (DPYD, DHP, DPD, DHPDHASE) testing. Microbiologics is the go-to partner and trusted expert in infectious disease diagnostic quality controls, focused on protecting the safety and health of people around the world. The company offers the broadest collection of third-party IVD controls for simple, reliable QC testing of traditional and molecular infectious disease diagnostics. Microbiologics also partners with diagnostic technology developers to design and manufacture custom biological materials for every step of the process, from conception through market adoption.

The integration of SensID's expertise will complement Microbiologics' comprehensive offerings, allowing for innovations that will drive the future of diagnostic testing. As the integration progresses, both companies will continue to prioritize delivering superior products and services to their customers, with no disruption to ongoing partnerships and projects. The combination of Microbiologics' infectious disease diagnostic solutions and SensID's molecular oncology expertise will ensure they are well-positioned to lead in the diagnostic quality control market.

"We are excited to welcome SensID into the Microbiologics team," said Kristen Knox, CEO of Microbiologics. "This partnership isn't just about expanding our capabilities; it's about bringing together two organizations who are deeply passionate about advancing the future of diagnostics. At the heart of everything we do is a commitment to improving the lives of patients and healthcare professionals around the world. By combining our expertise in infectious disease and oncology diagnostics, we can make an even greater impact."

"This partnership is a natural fit, not just because of our complementary expertise, but because our mission, vision, and values are so closely aligned," said Björn Nowack, CEO of SensID. "We've always prided ourselves on delivering high-quality, precisely characterized reference materials that are essential to advancing diagnostic testing. Joining forces with Microbiologics, a company that shares our dedication to excellence and patient safety, allows us to not only broaden our reach but also to continue innovating in ways we couldn't have done alone."

Related Links:
Microbiologics
SensID